News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
The researchers suggested that the regions they found should be included in diagnostic assays for unexplained cases of disorders of sex development.
The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.
The company and Women & Infants Hospital of Rhode Island are currently evaluating the technology to determine the performance of the test.
TwoXAR's proprietary artificial intelligence technology uses a variety of biomedical data including genomic, proteomic, and clinical data for drug discovery.
Researchers identified immune activity changes in first-trimester placenta and decidua samples profiled through single-cell RNA sequencing.
